Literature DB >> 24189640

The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer.

Farzad S Forootan1, Shiva S Forootan, Mohammed I Malki, Danqing Chen, Gandi Li, Ke Lin, Philip S Rudland, Christopher S Foster, Youqiang Ke.   

Abstract

The purpose of this study was to test the hypothesis that cooperative interaction between cutaneous fatty acid-binding protein (C-FABP) and peroxisome proliferator-activated receptors (PPAR) promotes the malignant progression of human prostate cancer. The expression of C-FABP, PPARβ/δ and PPARγ was measured by western blot analysis in prostate cell lines and by immunohistochemical staining in tissue sections of benign prostatic hyperplasia (BPH) and prostatic carcinomas. The correlation between the expression of PPARs and C-FABP was assessed. The significance of increased expression of these proteins was analysed with respect to prognosis and compared with those of alternative biomarkers. The expression levels of C-FABP and PPARγ in prostate cancer cell lines and the cytoplasm and nuclei of carcinoma tissues were significantly (Student's t-test, p<0.05) higher compared to those in benign cell lines and BPH tissues. The raised expression level of C-FABP and PPARγ was significantly correlated with the increased combined Gleason scores (GS) of the carcinomas. Enhanced expression of cytoplasmic C-FABP significantly correlated with increased nuclear PPARγ (Student's t-test, p<0.005). While expression of PPARβ/δ in carcinomas did not correlate with patient outcome, the increased levels of both C-FABP and PPARγ were associated with shorter patient survival. Multivariate analysis indicated that C-FABP was independently associated with patient survival, whereas PPARγ was confounded by C-FABP in predicting patient survival. Thus, the increased C-FABP may interact with PPARγ in a coordinated mechanism to facilitate malignant progression in prostatic cancer. Both C-FABP and PPARγ are suitable as prognostic factors to predict the clinical outcome of prostatic cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24189640     DOI: 10.3892/ijo.2013.2166

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  25 in total

1.  Prognostic role of PPAR-γ and PTEN in the renal cell carcinoma.

Authors:  Chaoyang Zhu; Jinxing Wei; Xin Tian; Yang Li; Xiaodong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Downregulation of fatty acid oxidation by involvement of HIF-1α and PPARγ in human gastric adenocarcinoma and related clinical significance.

Authors:  Rana Ezzeddini; Mohammad Taghikhani; Amir Salek Farrokhi; Mohammad Hossein Somi; Nasser Samadi; Ali Esfahani; Mohammad Javad Rasaee
Journal:  J Physiol Biochem       Date:  2021-03-17       Impact factor: 4.158

3.  Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.

Authors:  Gregory Carbonetti; Cynthia Converso; Timothy Clement; Changwei Wang; Lloyd C Trotman; Iwao Ojima; Martin Kaczocha
Journal:  Prostate       Date:  2019-10-29       Impact factor: 4.104

4.  Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.

Authors:  Hyung Kyu Park; HyunKyung Kim; Hyeong-Gon Kim; Young Mee Cho; Woon Yong Jung; Hye Seung Han; Tae Sook Hwang; Ghee Young Kwon; So Dug Lim
Journal:  J Korean Med Sci       Date:  2015-04-15       Impact factor: 2.153

5.  Proteomic Upregulation of Fatty Acid Synthase and Fatty Acid Binding Protein 5 and Identification of Cancer- and Race-Specific Pathway Associations in Human Prostate Cancer Tissues.

Authors:  Jennifer S Myers; Ariana K von Lersner; Qing-Xiang Amy Sang
Journal:  J Cancer       Date:  2016-07-05       Impact factor: 4.207

6.  Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma.

Authors:  Akihiko Takeuchi; Norio Yamamoto; Toshiharu Shirai; Katsuhiro Hayashi; Shinji Miwa; Seiichi Munesue; Yasuhiko Yamamoto; Hiroyuki Tsuchiya
Journal:  BMC Cancer       Date:  2016-07-11       Impact factor: 4.430

Review 7.  FABP5 as a novel molecular target in prostate cancer.

Authors:  Saoirse Elizabeth O'Sullivan; Martin Kaczocha
Journal:  Drug Discov Today       Date:  2020-09-20       Impact factor: 7.851

8.  Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.

Authors:  Farzad S Forootan; Shiva S Forootan; Xiaojun Gou; Jin Yang; Bichong Liu; Danqing Chen; Majed Saad Al Fayi; Waseem Al-Jameel; Philip S Rudland; Syed A Hussain; Youqiang Ke
Journal:  Oncotarget       Date:  2016-02-23

9.  High expression of Fatty Acid-Binding Protein 5 promotes cell growth and metastatic potential of colorectal cancer cells.

Authors:  Koichiro Kawaguchi; Shogo Senga; Chiaki Kubota; Yuki Kawamura; Youqiang Ke; Hiroshi Fujii
Journal:  FEBS Open Bio       Date:  2016-02-11       Impact factor: 2.693

10.  Metabolism-related enzyme alterations identified by proteomic analysis in human renal cell carcinoma.

Authors:  Zejun Lu; Yuqin Yao; Qi Song; Jinliang Yang; Xiangfei Zhao; Ping Yang; Jingbo Kang
Journal:  Onco Targets Ther       Date:  2016-03-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.